Axial Spondyloarthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia); and IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics for AxSpA that is refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and from the growing IL-17 class. In 2019, the FDA approved Cimzia for nonradiographic (nr)-AxSpA, marking the first FDA approval for this subpopulation. The FDA approved both IL-17 inhibitors in June 2020 and Rinvoq in October 2022. The recent approval of additional IL-17 inhibitor (UCB’s Bimzelx) and Cosentyx’s IV formulation as well as the potential approval of another JAK inhibitor (Galapagos’s filgotinib)—for ankylosing spondylitis (AS) and nonradiographic (nr)-AxSpA—will intensify the competition.

Questions answered:

• How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
• What are interviewed experts’ insights on current treatment options for AS and nr-AxSpA? What clinical needs remain unfulfilled?
• What pipeline products are the most promising, and what key therapies are in early-phase development?
• What are interviewed experts’ opinions of the use of Xeljanz and Rinvoq for AS? What sales / uptake could JAK inhibitors secure in AxSpA?
• What are the drivers of and constraints in the AxSpA therapy market, and how will the market evolve over the forecast period?

Content highlights:

Geographies: United States, EU5, Japan

Primary research: 29 country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.

Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2033, segmented by brands / generics and epidemiological subpopulations

Emerging therapies: Phase 3: 1 drug; Phase 2: 2 drugs

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.